– CANADA, Toronto – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) is pleased to announce the appointment of Mr. Luigi Gentile as Director to the company with official position and title to be announced alongside other additional board appointments within the next 2 to 3 weeks.

Luigi brings to Easton Pharmaceuticals a broad history of commercial leadership and innovation experience leading sales, marketing, product management and R&D teams in Healthcare. He has led several commercial leadership roles at start-ups, SMEs and large multinationals including GE Healthcare. There he held several positions, most recently Client Solutions Director, leading large strategic initiatives and teams bringing novel solutions to market across Canada. Prior to that, Luigi was the National Sales and Marketing leader for the GE Healthcare IT business, as well as Executive Director of a global innovation centre successfully brining new pathology modalities to market.

Additionally, Luigi served as VP of Sales and Marketing for Myndtec, launching a new medical device and therapy to markets aimed at helping stroke and spinal cord injury patients recover mobility in paralyzed limbs.

He has also previously held the roles of Regional Manager for Olympus Canada’s Scientific Equipment and Medical Imaging Group, as well as the Global Sales and Marketing Leader for EXFO Life Sciences.

Before industry, Luigi spent more than 10 years in clinical research and earned a Master’s in Physiology and Collaborative Master’s in Neuroscience from the University of Toronto.

Luigi will be assisting Easton with not just Easton’s most recent acquisitions such as Alliance venture partners and Easton’s Mexico, Latin America rollout of its licensed products including from CommonSense of Israel and the subsequent sub-distribution Agreements Easton has entered into as a result of, but will also be an essential and an integral part of assessing new synergistic opportunities for the company.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica and together own the exclusive distribution rights in Mexico and Latin America for patented women’s diagnostic / treatment products and two generic cancer drugs. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts. Easton has closed on an agreement to acquire 100% of iBliss Inc., a leading e-liquid vapor producer and distributor with international sales.

For more information : http://www.eastonpharmaceuticalsinc.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.